KPJ Healthcare Adopts IBM Watson for Oncology to Help Oncologists in Malaysia
Private Healthcare Services Provider is First In Malaysia to Adopt Watson for Oncology
KUALA LUMPUR, 27 November 2017 - KPJ Healthcare Berhad today announced it will adopt Watson for Oncology trained by Memorial Sloan Kettering (MSK), a cognitive computing platform, to provide insights that help doctors deliver evidence-based cancer treatment options.
KPJ is the first provider of private healthcare services in Malaysia to adopt Watson for Oncology, at its five specialist hospitals namely KPJ Damansara Specialist Hospital (KPJ Damansara), KPJ Ampang Puteri Specialist Hospital (KPJ Ampang Puteri), KPJ Johor Specialist Hospital (KPJ Johor), KPJ Ipoh Specialist Hospital (KPJ Ipoh) and KPJ Sabah Specialist Hospital (KPJ Sabah).
KPJ HealthCare Berhad And IBM Watson Press Conference Session.“We believe that introducing Watson for Oncology will increase KPJ’s capability to provide cancer patients with treatment options that are based on facts and medical evidence,” said KPJ Healthcare President and Managing Director, Dato’ Amiruddin Abdul Satar.
He added, “This investment in cognitive technologies is in line with KPJ’s vision to become an oncology hub in Malaysia and the region as our clinicians seek to continually deliver excellent care to the 3 million patients we serve each year.”
According to the Malaysian National Cancer Registry, cancer is the third most common cause of death among Malaysians at 14% after respiratory (19%) and circulatory (23%) diseases. Women have a higher risk of cancer compared to men with the most common type being breast cancer while colorectal and prostate cancer are common among men. Watson for Oncology was developed by IBM in collaboration with Memorial Sloan Kettering Cancer Center. It can summarize key medical attributes of a patient, and provide information to oncologists to help them deliver treatment options based on training from MSK oncologists. Watson for Oncology ranks the treatment options, linking to peer reviewed studies that have been curated by MSK.
“This latest collaboration with KPJ in Malaysia further expands IBM’s growing footprint of well-known healthcare institutions that are using Watson in the Asia Pacific region,” said Chong Chye Neo, Managing Director, IBM Malaysia. “KPJ is on the cutting edge in bringing cognitive computing into the clinical workflow to augment and scale the ability of their clinicians to bring quality care to their patients.”
☆☆☆☆
Fact Sheet: Watson for Oncology
What is Watson? 》
Watson represents a new era in computing called cognitive computing, where systems understand, reason and learn. With the help of Watson, organizations are harnessing the power of cognitive computing to transform industries and solve important Challenges. Watson solutions are being built, used and deployed in more than 45 countries and across 20 different industries. Watson is the only commercially available AI platform tackling a broad range of health challenges, from cancer to diabetes to clinical research. In oncology, Watson is in use at more than 80 hospitals and 11 countries around the world.
What is Watson for Oncology?
Watson for Oncology was developed by IBM in collaboration with Memorial Sloan Kettering Cancer Center (MSK) in New York. It can summarize key medical attributes of a patient, and provide information to oncologists to help them deliver treatment options based on training from MSK oncologists. Watson for Oncology ranks the treatment options, linking to peer reviewed studies that have been curated by MSK. Watson for Oncology also provides a large corpus of medical literature for a physician to consider, drawing on more than 300 medical journals, more than 200 textbooks, and nearly 15 million pages of text to provide insights about different treatment Options.
What kinds of cancer does Watson for Oncology support? 》
Watson for Oncology is available to assist clinicians in developing treatment plans for breast, lung, colorectal, cervical, ovarian, gastric, prostate and bladder cancers.
How does Watson for Oncology work? 》
Watson for Oncology can summarize key medical attributes of a patient, and provide information to oncologists to help them deliver treatment options based on training from MSK oncologists. The platform ranks the treatment options, linking to peer reviewed studies that have been curated by MSK. Watson for Oncology is available as a cloud-based Software as a Service (SaaS) technology, allowing clinicians to access Watson's capabilities as needed. Patient data is de-identified prior to Watson’s analysis.
How will KPJ Healthcare Berhad use Watson for Oncology? 》
KPJ Healthcare Berhad is the first hospital in Malaysia to adopt Watson for Oncology to advance evidencebased cancer care in Malaysia. With IBM Watson for Oncology, KPJ clinicians will be able evaluate the growing body of cancer research and data in combination with information specific to a patient’ to accelerate personalized treatment to individual patients.
How will this benefit patients at KPJ? 》
Cancer is now the third most deadly disease in Malaysia, and KPJ believes the advanced cognitive capabilities of Watson for Oncology will help to improve care decisions by oncologists. Watson for Oncology will assist KPJ oncologists with decision support for treatment options in their goal to provide every cancer patient the most advanced, efficacious and cost effective treatment if they are seen by a KPJ oncologist anywhere in the KPJ network.
Are there studies on Watson in cancer care? 》
A large, growing body of evidence supports the use of Watson in healthcare. For example, doctors at Manipal Hospitals reported data at A800 2017 that Watson for Oncology matched the recommendations of Manipal's multidisciplinary tumor board in up to 96% of lung cancer cases. Also at ASCO 2017, a stud led by Novartis and Highlands Oncology Group found in an initial pre-screening test that Watson for Clinical Trial Matching cut the clinical trial screening time by 78 percent.
The journal The Oncologist recently published an important study led by oncologists at the University of North Carolina’s Lineberger Comprehensive Cancer Center, who tested Watson for Genomics on 1,018 retrospective patient cases. More than 99 percent of the time, Watson for Genomics identified potential actionable treatment options that UNC's molecular tumor board had also identified, but in more than 300 cases, Watson found clinically actionable therapeutic options that the tumor board physicians had not identified. Another recent study published in Neurology Genetics found that Watson for Genomics accurately interpreted whole genome sequencing data for a glioblastoma patient in 10 minutes vs. 160 expert human hours.
Sources:
National Cancer Registry https://kpkesihatan.com/2016/12/07/the-malaysian-national-cancer-registry-report-mncr-2007-2011
Rise of cancer deaths in Malaysia http://www.thestar.com.my/news/community/2014/02/18/rise in-cancer-deaths-in msia-conference-and-expo-this-saturday-to-educate-public-on-how-to-deal-wit/
☆☆☆☆
About KPJ Healthcare Berhad 》
KPJ Healthcare Berhad (KPJ) is one of the leading private healthcare services providers in the region with a network of 25 hospitals in Malaysia, 2 in Indonesia, 1 in Bangladesh, 1 in Thailand and aged care centres in Kuala Lumpur, Sabah and Brisbane, Australia.
With more than 3,000 licensed beds, KPJ hospitals offer a comprehensive range of medical services and have treated more than 2.4 million outpatients and 300,000 inpatients in 2016. KPJ healthcare group portfolio includes hospital management, healthcare technical services, hospital development and commissioning, nursing, health sciences and continuous professional healthcare education, pathology services, central procurement and retail pharmacy.
About IBM Malaysia 》
For more information, please visit www.ibm.com.
0 Comments